Translate Bio is a clinical-stage messenger RNA (mRNA) therapeutics company. The company is engaged in developing medicines to treat diseases caused by protein or gene dysfunction. Using its proprietary mRNA therapeutic platform (MRT platform), the company creates mRNA that encodes functional proteins. The company is developing its MRT product candidate for the lung, MRT5005, for the treatment of cystic fibrosi, and MRT5201, for the treatment of ornithine transcarbamylase deficiency.
- ExchangeNASDAQ Stock Market
- SectorPharmaceuticals & Biotechnology
- CountryUnited States